Duraloglu, C. Et Al. 2024. Nintedanib and miR-29b co-loaded lipoplexes in idiopathic pulmonary fibrosis: formulation, characterization, and in vitro evaluation. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY , no.7 , 671-686.

Duraloglu, C., BAYSAL, İ., YABANOĞLU ÇİFTÇİ, S., & ARICA YEGİN, B., (2024). Nintedanib and miR-29b co-loaded lipoplexes in idiopathic pulmonary fibrosis: formulation, characterization, and in vitro evaluation. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY , no.7, 671-686.

Duraloglu, Ceren Et Al. "Nintedanib and miR-29b co-loaded lipoplexes in idiopathic pulmonary fibrosis: formulation, characterization, and in vitro evaluation," DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY , no.7, 671-686, 2024

Duraloglu, Ceren Et Al. "Nintedanib and miR-29b co-loaded lipoplexes in idiopathic pulmonary fibrosis: formulation, characterization, and in vitro evaluation." DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY , no.7, pp.671-686, 2024

Duraloglu, C. Et Al. (2024) . "Nintedanib and miR-29b co-loaded lipoplexes in idiopathic pulmonary fibrosis: formulation, characterization, and in vitro evaluation." DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY , no.7, pp.671-686.

@article{article, author={Ceren Duraloglu Et Al. }, title={Nintedanib and miR-29b co-loaded lipoplexes in idiopathic pulmonary fibrosis: formulation, characterization, and in vitro evaluation}, journal={DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY}, year=2024, pages={671-686} }